This recommendation statement from the Second Panel on Cost-Effectiveness in Health and Medicine reviews methodological advances in cost-effective analyses and updates the 1996 recommendations for the conduct and report of cost-effective analyses.
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
This study compares health care costs and outcomes for patients with joint replacement or sepsis before and after implementation of a value-drive outcomes program designed to give physicians information about clinical outcomes, costs, and variation.
This cohort study uses commercially available health care improvement database data to compare trends in the use, outcomes, and costs of robotic-assisted vs laparoscopic nephrectomy in the United States between 2003 and 2015.
You currently have no searches saved.